Filter
402
Text search:
XDR-TB
Featured
Recommendations
52
New Publications
107
Language
Document type
No document type
308
Studies & Reports
28
Guidelines
27
Situation Updates
12
Manuals
8
Training Material
6
Fact sheets
6
Strategic & Response Plan
5
Resource Platforms
1
Infographics
1
Countries / Regions
Western and Central Europe
44
Eastern Europe
31
South Africa
15
India
14
Namibia
9
Kenya
8
Tanzania
8
Bangladesh
8
Uganda
6
Nepal
6
Germany
6
Ukraine
6
Myanmar / Burma
6
Russia
6
Ethiopia
5
Zambia
5
Global
5
Botswana
4
Latin America and the Carribbean
4
Senegal
3
Ghana
3
Mozambique
3
Colombia
3
Asia
3
Armenia
3
Philippines
2
Malawi
2
Eswatini/ Swaziland
2
Lesotho
2
South–East Asia Region
2
Eastern Europe and Central Asia
2
Paraguay
2
Tajikistan
2
Georgia
2
Vietnam
2
Sierra Leone
1
Cambodia
1
Gambia
1
Rwanda
1
Indonesia
1
Peru
1
Madagascar
1
East and Southern Africa
1
West and Central Africa
1
Middle East and North Africa
1
Africa
1
Albania
1
Timor Leste/ East Timor
1
Estonia
1
Romania
1
Moldova
1
Kazakhstan
1
Turkmenistan
1
Azerbaijan
1
Belarus
1
Authors & Publishers
Publication Years
Category
Countries
138
Clinical Guidelines
40
Public Health
10
Capacity Building
7
Key Resources
4
Pharmacy & Technologies
4
Women & Child Health
1
Toolboxes
TB
258
HIV
28
AMR
18
Polio
9
Refugee
6
Ebola & Marburg
3
Pharmacy
3
NTDs
3
Caregiver
2
Disability
1
Rapid Response
1
Specific Hazards
1
COVID-19
1
2.0 Rapid Response
1
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr
...
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med
...
Towards ending tuberculosis and multidrug-resistant tuberculosis.
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
Tuberculosis (TB) is, and should be, a curable disease; however, each year significant numbers of patients acquire or develop drug-resistant TB, which has a much lower cure rate. Patients with drug-resistant TB have a high prevalence of symptoms; hence, staff caring for these patients should h
...
Towards a world free of tuberculosis
The Global Programme on Tuberculosis & Lung Health of the World Health Organization (WHO/GTB) is now combining all current recommendations into one overall set of consolidated guidelines on TB. The guidelines contain recommendations pertaining to all areas related to the programmatic management of T
...
Training for staff working at DR-TB management centres.
Training modules
Interim policy guidance
Tuberculosis cases, TB deaths
Version 1.0, 2014-11-21
Introduction:
This document lists TB indicators that can be derived from the recording and reporting tools defined
in Definitions and reporting framework for tuberculosis – 2013 revision (WHO/HTM/TB/2013.2).
Geneva, World Health Organization; 2013. (http://www.who.int/t
...
Zambia has completed the implementation of the National TB Strategic Plan (2017-2021) that set in motion the TB elimination agenda in Zambia through coordinated and accelerated TB response. During this period, the National TB and Leprosy Programme (NTLP) registered tremendous success.
The NTLP is
...
Tuberculosis (TB) remains a significant global health challenge, with an estimated annual death rate of approximately one per 100,000 people in countries with low TB prevalence. Rapid reductions in TB cases and deaths worldwide depend on research breakthroughs, including the development of new vac
...
